Les Pensières Veyrier-du-Lac (FRANCE) 7 - 18 May 2018 th Application deadline: 15 November 2017

For nearly 20 years, ADVAC has provided senior decision-makers and scientists in the field of with a comprehensive overview of the latest advances, from immunology to development, including clinical trials. The social, 19economic, political and ethical issues of are also addressed during the lectures, which are given by a faculty of leading global experts. 75 HIGHLY SELECTED PARTICIPANTS WHO SHOULD APPLY ? The fees include tuition and course materials for the full period of the course. • Scientists and decision-makers involved in 70 INTERNATIONAL SPEAKERS If selected, participants will be required to pay vaccine development, in the elaboration of all fees in full to confirm their participation. OVER 1,000 ADVAC ALUMNI WORLDWIDE new vaccination strategies or in policy 13 INTERACTIVE SESSIONS decisions related to the introduction of new Fellowships: vaccines in public health programmes, at Fellowships covering travel expenses, 11 DAYS OF KNOWLEDGE-SHARING national or international levels. registration and accommodation fees will be Through alumni get-together meetings The relationships forged at ADVAC • For both the public and private sectors. available for participants from low and 18 SUCCESSFUL YEARS and a variety of online resources remain strong through meetings middle income countries (with the support of Apply online through http://advac.org/ the Bill & Melinda Gates Foundation). They (website, newsletters), ADVAC organised during international 10 CASE STUDIES Deadline: 15 November 2017 at 12:00 GMT. will be handled by the Center of Vaccinology continues to bring together vaccinologists conferences such as SAGE, at the University of Geneva and the Mérieux 1 DIPLOMA AND CME CERTIFICATE SELECTION CRITERIA Foundation. Fellowships will also be provided throughout the world to discuss the ESPID (European Society for to selected ESPID members. Candidates Participants (maximum 75) will be selected wishing to apply for such fellowships should major challenges of the day. Paediatric Infectious Diseases), A NETWORK OF OVER 1,000 ALUMNI by the international scientific committee, tick the appropriate box on their application ICAAC (Interscience Conference according to their: and if selected, ADVAC organisers will inform Past editions of ADVAC have been awarded • Educational background, on Antimicrobial Agents and the relevant fellowship provider. CME credits. For the 19th ADVAC, CME credits • Involvement in vaccinology, Chemotherapy) or IDSA (Infectious will again be requested from the European • Decision-making responsibility in vaccinology, • Expected impact of the course at personal, VENUE Diseases Society of America). Union of Medical Specialists - European institutional and national levels (maximum The course will be held at Accreditation Council for Continuing Medical one participant per institution). the Mérieux Foundation’s conference centre, http://advac.globe-network.org/en Education (UEMS-EACCME). CME credits can Les Pensières Center for Global Health, at be converted by the American Medical PROGRAMME FEES Veyrier-du-Lac, on the scenic banks of Lake Annecy (France). Association (AMA). Accommodation fees: 2,400 € théra - RCS Lyon B 398 160 242 with and • Johns Hopkins Fellowships for low and Accommodation will be arranged in nearby Organised by Registration fees: the co-sponsorship of Bloomberg School of middle income country hotels. • Participants from academic/governmental The Mérieux Foundation • European Centre Public Health participants provided by institutions & NGOs benefit from reduced and University • European for Disease • National Foundation Commission (EDCTP) Prevention and • Bill & Melinda Gates fees: 1,500 € VAT included CONTACT for Infectious of Geneva • World Health Control (ECDC) Foundation • Participants from industry: Diseases (NFID) Katia Mielczarek Organization • Centers for Disease SME and ADVAC sponsors from industry: • National Institutes [email protected] Control and

C 100 of Health (NIH) and C 100 M 72 4,000 € M 72 J 0 J 0 N 32 or [email protected] Prevention (CDC) N 32 Pantone : 281 C Other industry participants: 9,000 € Fogarty International Pantone : 281 C See additional info on http://advac.org/ • European Society for Center www.fondation-merieux.org Paediatric Infectious • National Vaccine Diseases (ESPID) Programme Office (NVPO) 05-17 - Credit photo: • E. BERGOEND A. BOUVIER F.LECLERC Objective: to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the field, from immunology to vaccine development, including clinical trials and the social, economic, political and ethical issues of vaccination.

PROVISIONAL PROGRAMME CORE FACULTY SCIENTIFIC COMMITTEE SESSION 1 SESSION 4 SESSION 8.1 THE MULTI-FACETED NATURE OF VACCINOLOGY ASSESSING VACCINES IN CLINICAL TRIALS (I) INTRODUCING NEW VACCINES INTO ROY ANDERSON MYRON LEVINE PAUL-HENRI LAMBERT (Course Director) • Access to vaccination in GAVI countries • Sequential stages of clinical trials VACCINATION PROGRAMMES Imperial College London, UK University of Maryland, USA University of Geneva, Switzerland and, at global level, impact of vaccination and overview of issues to be considered • Approaches to help the decision-making EDWIN ASTURIAS NONI MCDONALD (Senior Scientific Advisor) on disease • How to design, recruit volunteers for, and process Children’s Hospital Colorado, USA Dalhousie University, Canada • Are vaccines always cost-effective? analyse the results of selected phase II trials • Role of epidemiology and the economy Vaxconsult, USA NORMAN BAYLOR MARK MILLER • How to develop a new programme of • How to design a phase II trial • Case-specific studies: EDWIN ASTURIAS BCG, USA Fogarty International Center, NIH, USA immunisation Meningococcal vaccines, Combination Children’s Hospital Colorado, USA ADVAC helps fulfill • Industrial vision of vaccinology in SESSION 5 vaccines, Influenza-vaccination strategies, RON DAGAN RICHARD MOXON PHILIPPE DUCLOS WHO, Switzerland the prescient vision of industrialised and developing countries ASSESSING VACCINES IN CLINICAL TRIALS (II) Pneumococcal conjugates, HPV, , Soroka Medical Center, Israel Oxford University, UK JE, Dengue • Lessons from pitfalls experienced PHILIPPE DUCLOS PIETER NEELS ADAM FINN University of Bristol, UK “Dr. Charles Mérieux to gather SESSION 2 • Group exercises: selected countries Neal Halsey, in the registration process WHO, Switzerland Vaccine-Advice, Belgium BRUCE GELLIN NVPO, USA HOW VACCINES WORK Professor - Department scientists and other health • Clinical trials: role of a Data and Safety JANET ENGLUND KATHY NEUZIL SESSION 8.2 NEAL HALSEY of International Health, professionals to address the • How are vaccine responses elicited? Monitoring Board (DSMB) Seattle Children’s Hospital, USA CVD Baltimore, USA Bloomberg School of Public • Immunological basis for responses • Designing and analysing the results INTRODUCING NEW VACCINES INTO J.H. Bloomberg School of Public Health, USA Health, Baltimore VACCINATION PROGRAMMES ADAM FINN HANNA NOHYNEK never-ending challenges from to mucosal vaccines of 3 selected phase III trials CAROLE HEILMAN University of Bristol, UK National Institute for Health and Welfare, infectious diseases. • Immunological correlates of immunity • Vaccination in the elderly Formerly NIAID, NIH, USA • Vaccines and immunological memory SESSION 6 • Influenza biology BERNARD FRITZELL Finland BFL Conseils, France ORIN LEVINE Past ADVAC participants have VACCINE SAFETY • New vaccines: Malaria, Tuberculosis, HIV, RSV UMESH PARASHAR SESSION 3 • Rotavirus vaccines DAVID GOLDBLATT CDC, USA Bill & Melinda Gates Foundation, USA helped bring new lifesaving • Lessons from previous adverse effects • Dengue vaccines Institute of Child Health, University College DECISION-MAKING IN VACCINE R&D of vaccination and assessment of causal ANDREW POLLARD KARI JOHANSEN ECDC, Sweden vaccines to countries • HPV vaccines London, UK • New approaches to vaccine development relationships Oxford University, UK MICHAEL MAKANGA EDCTP, throughout the world and they and delivery • Immunological safety of vaccination RANA HAJJEH SESSION 9 STANLEY PLOTKIN the Netherlands • How do vaccines cause adverse events • Population-based post-licensure WHO-EMRO Vaxconsult, USA are playing key roles in the SELECTING APPROPRIATE VACCINATION MARK MILLER • From pre-clinical research to vaccine surveillance DEBORAH HALL STRATEGIES DAVID SALISBURY development of new vaccines. development • Immunisation safety in developing country Journalist, UK Bethesda, USA • Vaccine adjuvants: pragmatic approaches vaccination programmes • Vaccines for maternal-neonatal health Chatham House, UK NEAL HALSEY HANNA NOHYNEK THL, Finland • and risk communication: • Vaccination schedules CLAIRE-ANNE SIEGRIST J.H. Bloomberg School of Public Health, USA an overview • Elimination and eradication strategies University of Geneva, Switzerland CLAIRE-ANNE SIEGRIST ” CAROLE HEILMAN CATHERINE SLACK University of Geneva, Switzerland SESSION 7 SESSION 10 Formerly NIAID, NIH, USA University of KwaZulu-Natal, South Africa KEIPP TALBOT NFID, USA KARI JOHANSEN ETHICAL ISSUES FACING THE MEDIA PETER SMITH ECDC, Sweden MELINDA WHARTON CDC, USA • Ethical issues related to clinical trials • Introduction to media dynamics: London School of Hygiene & Tropical • Group exercises How to best deliver vaccinology-related PAUL-HENRI LAMBERT Medicine, UK ANNELIES WILDER-SMITH messages to different interest groups University of Geneva, Switzerland Mérieux Foundation, France